Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02913794

Acronym

FIMARO

Enrollment

541

Registered

2016-09-26

Start date

2016-10-11

Completion date

2018-03-29

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Hyperlipidemias

Brief summary

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more. * Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more * Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, \* TG) checks 2 weeks before registration

Exclusion criteria

* Patients being hospitalized * Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days * Patients who have more than 400mg/dl triglyceride(TG) at the registration time

Design outcomes

Primary

Measure	Time frame	Description
Co-relation between blood pressure and dyslipidemia	12 weeks	Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease

Countries

South Korea

Outcome results